1. Home
  2. ZNTL vs RDIB Comparison

ZNTL vs RDIB Comparison

Compare ZNTL & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • RDIB
  • Stock Information
  • Founded
  • ZNTL 2014
  • RDIB 1937
  • Country
  • ZNTL United States
  • RDIB United States
  • Employees
  • ZNTL N/A
  • RDIB N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • RDIB Movies/Entertainment
  • Sector
  • ZNTL Health Care
  • RDIB Consumer Discretionary
  • Exchange
  • ZNTL Nasdaq
  • RDIB Nasdaq
  • Market Cap
  • ZNTL 137.9M
  • RDIB 140.2M
  • IPO Year
  • ZNTL 2020
  • RDIB N/A
  • Fundamental
  • Price
  • ZNTL $1.63
  • RDIB $7.02
  • Analyst Decision
  • ZNTL Buy
  • RDIB
  • Analyst Count
  • ZNTL 8
  • RDIB 0
  • Target Price
  • ZNTL $8.53
  • RDIB N/A
  • AVG Volume (30 Days)
  • ZNTL 852.5K
  • RDIB 12.3K
  • Earning Date
  • ZNTL 03-26-2025
  • RDIB 05-14-2025
  • Dividend Yield
  • ZNTL N/A
  • RDIB N/A
  • EPS Growth
  • ZNTL N/A
  • RDIB N/A
  • EPS
  • ZNTL N/A
  • RDIB N/A
  • Revenue
  • ZNTL $67,425,000.00
  • RDIB $210,527,000.00
  • Revenue This Year
  • ZNTL N/A
  • RDIB N/A
  • Revenue Next Year
  • ZNTL N/A
  • RDIB $18.29
  • P/E Ratio
  • ZNTL N/A
  • RDIB N/A
  • Revenue Growth
  • ZNTL N/A
  • RDIB N/A
  • 52 Week Low
  • ZNTL $1.58
  • RDIB $5.78
  • 52 Week High
  • ZNTL $16.27
  • RDIB $21.34
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 36.50
  • RDIB 46.06
  • Support Level
  • ZNTL $1.78
  • RDIB $6.06
  • Resistance Level
  • ZNTL $2.02
  • RDIB $12.30
  • Average True Range (ATR)
  • ZNTL 0.15
  • RDIB 1.08
  • MACD
  • ZNTL -0.00
  • RDIB -0.18
  • Stochastic Oscillator
  • ZNTL 3.53
  • RDIB 15.38

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

About RDIB Reading International Inc Class B

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.

Share on Social Networks: